Viewing Study NCT02926768

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:53 PM
Ignite Modification Date: 2026-02-26 @ 12:04 PM
Study NCT ID: NCT02926768
Status: COMPLETED
Last Update Posted: 2022-07-26
First Post: 2016-09-29
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
Sponsor: Checkpoint Therapeutics, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lung Neoplasms View
None Carcinoma, Non-Small-Cell Lung View
None Lung Diseases View
None Adenocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Cancer View
None Non Small Cell Lung Cancer View
None EGFR sensitivity mutation View
None T790M View
None NSCLC View
None epidermal growth factor receptor View
None EGFR View
None EGFR inhibitor View